This post was originally published on this site
PARIS (Reuters) – Healthcare companies Sanofi (NASDAQ:SNY) and partner Regeneron (NASDAQ:REGN) presented on Tuesday more positive data for their Dupixent product.
The companies said new data showed that Dupixent showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.
